Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 11/20 | 0.71 |
| ▸ | SLC6A4 known ✓ | P31645 | 9/20 | 0.71 |
| ▸ | SLC6A3 known ✓ | Q01959 | 6/20 | 0.71 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.68 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.68 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.68 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637250 | 0.98 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL8038687 | 0.98 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL12188002 | 0.98 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Hydrogen Sulfide SCHEMBL28158135 | 0.97 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Acetic Acid SCHEMBL3036343 | 0.92 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Formic Acid SCHEMBL27642652 | 0.92 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Oxalic Acid SCHEMBL3710175 | 0.92 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Sulfuric Acid SCHEMBL27999742 | 0.92 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL753629 | 0.89 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL5815212 | 0.87 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043999-A2 | A PROCESS FOR THE PREPARATION OF VENLAFAXINE HYDROCHLORIDE | Aarti Healthcare Limited (IN) | 2009-04-08 | — | — | EP | claimed |
| EP-1824815-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL) ETHYL]CYCLOHEXANOL HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-29 | — | — | EP | claimed |
| WO-2007069277-A2 | A PROCESS FOR THE PREPARATION OF VENLAFAXINE HYDROCHLORIDE | AARTI HEALTHCARE LIMITED (IN) | 2007-06-21 | — | — | WO | claimed |
| US-20070129562-A1 | Process for the preparation of highly pure 1-[2- dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2007-06-07 | — | — | US | claimed |
| WO-2007047972-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL) ETHYL]CYCLOHEXANOL HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-04-26 | — | — | WO | claimed |
| CN-113429303-B | Industrial production method of venlafaxine hydrochloride | 合肥华方医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-113429303-A | Method for industrially producing venlafaxine hydrochloride | 合肥华方医药科技有限公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-112159330-A | Preparation method of venlafaxine hydrochloride intermediate | 苏州第四制药厂有限公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-102093233-A | Method for preparing 1-[2-amino-1-(p-methoxy phenyl) ethyl] cyclohexanol hydrochloride | SHANGHAI ECUST BIOMEDICINE CO LTD | 2011-06-15 | — | — | CN | disclosed |
| CN-102093233-A | Method for preparing 1-[2-amino-1-(p-methoxy phenyl) ethyl] cyclohexanol hydrochloride | SHANGHAI ECUST BIOMEDICINE CO LTD | 2011-06-15 | — | — | CN | disclosed |
| US-20100121108-A1 | PROCESS FOR SYNTHESIZING DESVENLAFAXINE FREE BASE AND SALTS OR SOLVATES THEREOF | MEDICHEM, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| EP-2061750-A2 | IMPROVED PROCESS FOR SYNTHESIZING DESVENLAFAXINE FREE BASE AND SALTS OR SOLVATES THEREOF | Medichem, S.A. (ES) | 2009-05-27 | — | — | EP | disclosed |
| WO-2007049302-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF PURE VENLAFAXINE | IND-SWIFT LABORATORIES LIMITED (IN) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007047972-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL) ETHYL]CYCLOHEXANOL HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-04-26 | — | — | WO | disclosed |
| US-7141697-B2 | Process for the preparation of phenethylamine derivatives | SANDOZ AG (CH) | 2006-11-28 | — | — | US | disclosed |
| EP-1721889-A1 | Process for the preparation of phenethylamine derivatives | Dishman Pharmaceuticals & Chemicals Ltd. (IN) | 2006-11-15 | — | — | EP | disclosed |
| EP-1343750-B1 | PROCESS FOR THE PREPARATION OF PHENETHYLAMINE DERIVATIVES | CIBA SC HOLDING AG (CH) | 2005-01-26 | — | — | EP | disclosed |
| EP-1343750-A1 | PROCESS FOR THE PREPARATION OF PHENETHYLAMINE DERIVATIVES | Ciba SC Holding AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20030114711-A1 | Process for the preparation of phenethylamine derivatives | SANDOZ AG (CH) | 2003-06-19 | — | — | US | disclosed |
| WO-2002050017-A1 | PROCESS FOR THE PREPARATION OF PHENETHYLAMINE DERIVATIVES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129562-A1 | Process for the preparation of highly pure 1-[2- dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride | HTR1F, CYP2F1, HTR1A | SLC6A2 49/4885SLC6A4 68/4885SLC6A3 92/4885 |
| US-20100121108-A1 | PROCESS FOR SYNTHESIZING DESVENLAFAXINE FREE BASE AND SALTS OR SOLVATES THEREOF | SLC6A4, VGF, SLC6A2 | SLC6A2 3/4885SLC6A4 1/4885SLC6A3 5/4885 |
| US-20030114711-A1 | Process for the preparation of phenethylamine derivatives | HNMT, HRH3, HRH1 | SLC6A2 119/4885SLC6A4 363/4885SLC6A3 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.